Morgan Stanley Initiates Coverage On Belite Bio with Overweight Rating, Announces Price Target of $191

Benzinga · 01/06 15:45
Morgan Stanley analyst Judah Frommer initiates coverage on Belite Bio (NASDAQ:BLTE) with a Overweight rating and announces Price Target of $191.